Showing 371-380 of 2700 results for "".
Comorbidities in Alopecia Areata
https://practicaldermatology.com/issues/july-2025/comorbidities-in-alopecia-areata/36507/Alopecia areata (AA) is a chronic, relapsing immune-mediated disorder that causes nonscarring hair loss that can significantly impact a patient’s quality of life.Biologics for Psoriasis: A Status Update
https://practicaldermatology.com/topics/psoriasis/biologics-for-psoriasis-a-status-update/23006/The field has grown substantially from the early 2000s to include now a dozen innovator systemic agents, a host of biosimilars, and soon JAK Inhibitors.Non-genital Warts: A Review of Current Treatments
https://practicaldermatology.com/topics/general-topics/non-genital-warts-a-review-of-current-treatments/21884/When determining which treatment modality to choose for non-genital warts, there are several factors to consider, including the convenience of the treatment, patient discomfort, location of warts, and potential side effects.Hyperpigmentation in Darker Skin Types: A Review of Current Treatments
https://practicaldermatology.com/programs/practical-dermatology/hyperpigmentation-in-darker-skin-types-a-review-of-current-treatments/24217/Pigmentary disorders are a leading concern for patients and consumers worldwide.What’s Really in a “Collagen” Supplement?
https://practicaldermatology.com/youngmd-connect/resident-resource-center/whats-really-in-a-collagen-supplement/23579/Concerns about lack of transparency of sourcing, potential for allergic reactions, and reports of contamination have been associated with collagen supplements.Diverse by Design: The Unique Molecular Footprints of IL-23 Biologics in Psoriasis
https://practicaldermatology.com/issues/april-2024/il23_biologics_in_psoriasis/24457/Christopher Bunick, MD, PhD, discusses a study that explores the structural basis of IL-23 targeted biologic therapies for psoriasis. By mapping the binding sites of these therapies on the IL-23 molecule and correlating molecular properties with clinical efficacy, the study offers insights into whyGLP-1 Receptor Agonists and the Aesthetic Patient: Considerations for the Dermatologist
https://practicaldermatology.com/issues/novemberdecember-2025/glp-1-receptor-agonists-and-the-aesthetic-patient/48900/The impact of glucagon-like peptide-1 agonists (GLP-1), such as semaglutide, tirzepatide and liraglutide, has transformed the healthcare industry and, in particular, aesthetic dermatology. The most common intended use of these medications, namely diabetes management and weight loss, can lead to a muOpen Payments Program: Does it Enhance Open Discussion About Financial Ties Between Dermatologists and Industry?
https://practicaldermatology.com/youngmd-connect/resident-resource-center/open-payments-program-does-it-enhance-open-discussion-about-financial-ties-between-dermatologists-and-industry/23619/The majority of physicians practicing in the United States have received some form of compensation from private industry during their careers. These payments may include consulting fees, compensation for speaking engagements, and stock options. Certain payments take indirect forms, such as physicAGEP Following a New Weight Loss Regimen
https://practicaldermatology.com/youngmd-connect/resident-resource-center/agep-following-a-new-weight-loss-regimen/23719/A 55-Year-Old Man with Erythematous Papules Following a New Weight Loss RegimenDo You Own Real Estate in Your Practice?
https://practicaldermatology.com/topics/practice-management/do-you-own-real-estate-in-your-practice/20783/Five tips for dermatologists considering the sale of real estate to REIT.